Elizabeth C. Verna

2/4-The INTEGRATE Study: Evaluating INTEGRATEd Care to Improve Biopsychosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease

National Institute on Alcohol Abuse and Alcoholism · R01

Contact PI · $1.7M · Columbia University Health Sciences

Molecular Mechanisms by Which Statins Prevent and Reverse Hepatocellular Carcinoma

National Cancer Institute · U01

PI · $1.3M · Stanford University

Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network

National Institute of Diabetes and Digestive and Kidney Diseases · U01

PI · $3M · Weill Medical Coll of Cornell Univ

Gut Microbiota in the Modulation of Outcomes After Liver Transplant

National Center for Advancing Translational Sciences · R21

PI · $447.6K · Virginia Commonwealth University

Boceprevir in End Stage Renal Disease (ESRD)

Principal investigator · Withdrawn

Columbia University

Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant

Principal investigator · Unknown · Phase 2

Columbia University